Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balovaptan in Children 2-4 Years With ASD
NCT04049578Phase 1Terminated
- Sponsor
- Roche
- Start
- Dec 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of balovaptan in Autism Spectrum Disorder (ASD), sponsored by Roche. Primary endpoints: Area Under the Curve at Steady State of Balovaptan at Week 54, Plasma Concentration of Balovaptan at Week 54 and 2 more. Started Dec 2019; status: terminated.
02
Drugs
balovaptan
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04049578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049578.